There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > APRIL


APRIL Molecule Information

Name:Tumor necrosis factor ligand superfamily member 13
Target Synonym:A proliferation-inducing ligand;CD_antigen=CD256;TRDL-1;TNF-related death ligand 1;TNF- and APOL-related leukocyte expressed ligand 2;APRIL;APRIL ;Tumor necrosis factor ligand superfamily member 13;TALL-2;TNFSF13;TALL2;ZTNF2
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:7
Lastest Research Phase:Phase ?

APRIL Protein Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
Cat. No. Species Product Description Structure Purity Feature
APL-H82F5 Human Biotinylated Human APRIL / TNFSF13 Protein, Fc,Avitag™
APL-H5244 Human Human APRIL / TNFSF13 Protein, His Tag
APL-H5267 Human Human APRIL / TNFSF13 Protein, Fc Tag

APRIL Molecule Synonym Name


APRIL Molecule Background

APRIL(a proliferation-inducing ligand) is also known as Tumor necrosis factor ligand superfamily member 13, TALL-2, TRDL-1, CD256, TNFFSF 13, cytokine that binds to TNFRSF13B/TACI and to TNFRSF17/BCMA. APRIL is a cytokine of the tumor necrosis factor family associated mainly with hematologic malignancies. The closely related TNF family ligands B cell activation factor (BAFF) and a proliferation-inducing ligand (APRIL) serve in the generation and maintenance of mature B-lymphocytes. Both BAFF and APRIL assemble as homotrimers that bind and activate several receptors that they partially share. BAFF-APRIL heteromers of different stoichiometries have distinct receptor-binding properties and activities. In addition, expression of APRIL was regulated by miR-145 in GC cells.

APRIL References

APRIL Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Migis-mIgA (Tanox) VIS-649 Phase Ⅰ Visterra IgA nephropathy Details
BION-1301 BION-1301,BION1301 Phase Ⅱ Aduro BioTech Multiple myeloma (MM) Details
Anti-BCMA CAR T-cell therapy (Huazhong University of Science and Technology) Phase Not Specified Huazhong University of Science and Tech Plasma cell myeloma Details
VIS-649 (Visterra) VIS-649 Phase Ⅰ Visterra IgA nephropathy Details
bb-21217 bb-21217,bb 21217,bb21217 Phase Ⅰ bluebird bio, Celgene Multiple myeloma (MM) Details
BCMAxCD3 bispecific antibody (Regeneron) REGN-5458 Phase Ⅱ Regeneron Pharmaceutical, Sanofi Multiple myeloma (MM) Details
Telitacicept RCT-18; RC-18,RCT18; RC18 BLA Filing Remegen Systemic lupus erythematosus, Rheumatoid arthritis (RA), Neuromyelitis optica (NMO) Details
Atacicept TACI-Ig Phase Ⅲ ZymoGenetics, Merck Serono Chronic lymphocytic leukemia (CLL), Lupus nephritis, Multiple myeloma (MM), Systemic lupus erythematosus, Multiple sclerosis (MS), Rheumatoid arthritis (RA), Non-Hodgkin's lymphoma (NHL) Details

This web search service is supported by Google Inc.